U.S. & U.K. payers want greater discounts on Orkambi

Both the state of New York and NHS England have requested that Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) provide a lower price for its cystic fibrosis drug Orkambi ivacaftor/lumacaftor, but the biotech is unlikely to do so -- at least at the level requested by New York’s Medicaid program.

On April 26, the New York state Drug Utilization Review (DUR) board voted 10-0 to seek a supplemental rebate from Vertex to bring

Read the full 693 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers